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The Immunophilin FKBP12 Functions as a Common
Inhibitor of the TGFb Family Type I Receptors
Tongwen Wang,*‡ Bi-Yu Li,*‡ Paul D. Danielson,* (Ebner et al., 1993; Wrana et al., 1994a). The recent
Paresh C. Shah,* Sybil Rockwell,* discovery of a mutant type I receptor with a constitu-
Robert J. Lechleider,† Jennifer Martin,* tively active kinase, able to signal in the absence of
Thomas Manganaro,* and Patricia K. Donahoe* the type II receptor and TGFb, suggests that the type I
*Pediatric Surgical Research Laboratories receptor is responsible for initiating the downstream
Massachusetts General Hospital signaling pathway subsequent to its activation by the
Department of Surgery type II receptor (Wieser et al., 1995).
Harvard Medical School Little isknown about how the type II receptor activates
Boston, Massachusetts 02114 the type I receptor. Upon TGFb binding, the type II re-
†Laboratory of Chemoprevention ceptor forms heteromeric complexes with and is known
National Cancer Institute to phosphorylate the type I receptor within a serine/
9000 Rockville Pike, 41/C629 threonine rich domain located immediately amino-termi-
Bethesda, Maryland 20892 nal to the kinase domain of the type I receptor (the GS
box), although all phosphorylation sites on the type I
receptor have yet to be mapped (Wrana et al., 1994a,
Summary 1994b). Type II receptor-mediated type I receptor phos-
phorylation could activate the type I receptor kinase by
The immunophilin FKBP12 is an evolutionarily con- either inducing a conformational change of the type I
served abundant protein; however, its physiological receptor to directly activate the kinase activity, or by
roles remain poorly defined. Here we report that creating binding sites for activators or abolishing bind-
FKBP12 is a common cytoplasmic interactor of TGFb ing sites for inhibitors. To fully understand the molecular
family type I receptors. FKBP12 binds to ligand-free details involved in the activation of the type I receptor,
TGFb type I receptor, from which it is released upon it is therefore essential to identify and characterize the
a ligand-induced, type II receptor mediated phosphor- cytoplasmic interactors of the type I receptors before
ylation of the type I receptor. Blocking FKBP12/type I and after ligand binding.
receptor interaction with FK506 nonfunctional deriva- We previously isolated the immunophilin FKBP12 as
tives enhances the ligand activity, indicating that
a specific cytoplasmic interactor of a member of the
FKBP12 binding is inhibitory to the signaling pathways
TGFb family type I receptors (Wang et al., 1994). FKBP12of the TGFb family ligands. Overexpression of a myris-
is known to mediate the immunosuppressive activitiestylated FKBP12 in Mv1Lu cell specifically inhibits two
of two macrolides, FK506 and rapamycin, by binding toseparate pathways activated by TGFb, and two point
the macrolides and then recruiting, and thereby inacti-mutations on FKBP12 (G89P, I90K) abolish the inhibi-
vating, the serine/threonine phosphatase calcineurintory activity of FKBP12, suggesting that FKBP12 may
and the serine kinase FRAP (or RAFT1), respectively,dock a cytoplasmic protein to the type I receptors to
resulting in the blockage of the signaling pathways me-inhibit TGFb family mediated signaling.
diated by calcineurin or FRAP (Harding et al., 1989; Sie-
kierka et al., 1989; Liu et al., 1991, 1992; Clipstone and
Crabtree, 1992; Brown et al., 1994; Sabatini et al., 1994;Introduction
Brown et al., 1995; Zheng et al., 1995). Since FKBP12
is ubiquitous in virtually all mammalian cell types andThe transforming growth factor b (TGFb) family consists
is highly conserved from plants to mammals, its physio-of many structurally related small peptides, which regu-
logical role is likely to be very important.late a wide range of critical cell growth and differentia-
Here we provide evidence that one physiological roletion events (Moses et al., 1990; Border and Ruoslahti,
of FKBP12 is to inhibit the TGFb family type I receptor1992; Roberts and Sporn, 1993; Attisano et al., 1994;
mediated signaling pathways, possibly by serving as aKingsley, 1994; Massague´ et al., 1994). Two types of
docking protein for a cytoplasmic inhibitor, e.g. cal-single transmembrane serine/threonine kinase recep-
cineurin, to the cytoplasmic domains of these receptorstors, the type I and type II, have been found to mediate
the cellular effects of the TGFb family ligands. Molecular and thereby regulating their signaling activities. Fur-
characterization of the type I and the type II receptors ther, we demonstrate that in the presence of ligand, the
of the prototypical TGFb revealed that the two types of TGFb type II receptor phosphorylates the type I receptor
receptors play different roles in mediating downstream within an undefined site, leading to the release of
signaling. The type II receptor is a constitutively active FKBP12, which may be essential for the activation of the
serine/threonine kinase receptor that can bind TGFb type I receptors. The serine-threonine phosphorylation-
independently, but cannot signal without the type I re- dependent release of FKBP12, and another cytoplasmic
ceptor (Wrana et al., 1992). The type I receptor can only interactor (FNTA) (Wanget al., 1996), suggests that TGFb
bind to TGFb in the presence of the type II receptor family members signal via a novel mechanism distinct
from those known to be employed by the members of
the receptor tyrosine kinase family.‡Both contributed equally to the project, as co-first authors.
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Table 1. Summary of Results of Three Yeast Two-Hybrid
Screens Using Different Cytoplasmic Domains of Type I
Receptors as Bait
Baits Library FKBP12 (#/total positives)
R1C rat neonatal heart rFKBP12 (57/76)
R4C human fetal brain hFKBP12 (54/109)
TKV-C Drosophila imaginal disc Dr FKBP12 (38/38)
The entire cytoplasmic domain of R1 (He et al., 1993), R4 (He et al.,
1993, Bassing et al., 1994), or Thickvein (Tkv) (Brummel et al., 1994)
was fused in frame with the DNA binding domain LexA to serve as the
baits in the yeast two-hybrid screens. h, human; r, rat; Dr FKBP12, a
novel cDNA isolated from a Drosophila imaginal disc library.
Results and Discussion
FKBP12 Is a Specific Interactor for Multiple Type I
Receptors of the TGFb Family
Using a modified yeast two-hybrid system, we pre-
viously isolated the immunophilin FKBP12 as a candi-
date cytoplasmic interactor of one member (R1) of the
type I receptor family (Wang et al., 1994). In order to
isolate interactors specific for each of the known type I
Figure 2. Interaction between FKBP12 and Ligand-Free TGFb Type
receptors, we screened two additional yeast expression I Receptor (R4) in COS Cells
libraries using cytoplasmic domains of twodifferent type
COS1 cells were transiently transfected with the indicated plasmids,
I receptors as baits. FKBP12 was again isolated as the metabolically labeled with [35S]-methionine. Cell lysates were then
predominant interactor for each type I receptor. A novel immunoprecipitated with 5 ml of anti-T7 monoclonal antibody, and
the immunoprecipitates were separated on 15% SDS–PAGE, whichcDNA that is 66% identical to mouse FKBP12 was
was then visualized by autoradiography. FKT7, bacteria T7 epitopeisolated from a Drosophila imaginal disc cDNA library
is tagged at theamino terminus of FKBP12 andsubcloned in pCMV8.as the only interactor for the decapentaplegic (DPP)
R4, R4 pCMV6; R4K2, R4 (K230R) pCMV6; EV, pCMV6. The immuno-
type I receptor Thickvein (Tkv) (Brummel et al., 1994), precipitated FKT7 and the coprecipitated R4 are indicated.
and was thus designated the Drosophila FKBP12 (Dr
FKBP12) (T. W. et al., unpublished data). The results of
the three screens are summarized in Table 1. To determine whether FKBP12 also interacts with
other known type I receptors, five different mammalian
type I receptors (R1–R4, and ALK6) (He et al., 1993; ten
Dijke et al., 1993, 1994), two Drosophila type I receptors
(Sax and Tkv) (Brummel et al., 1994; Xie et al., 1994),
and three mammalian type II receptors (tRII, aRII, mRII,
type II receptors for TGFb, activin, and Mu¨llerian inhib-
iting substance [MIS], respectively) (Mathews and Vale,
1991; Lin et al., 1992; Teixeira et al., 1996) were tested
for interaction with FKBP12, in the yeast two-hybrid
system (Figure 1A). All tested type I receptors exhibited
strong interaction with FKBP12, while the tested type II
receptors did not, which indicates that FKBP12 is a
specific interactor for all type I receptors.
FKBP12 Binds to the TGFb Type I Receptor
in the Absence of TGFb
To confirm thespecific interaction between FKBP12 and
the cytoplasmic domains of the type I receptors ob-
served in yeast, we further tested the interaction be-
tween FKBP12 and the known functional TGFb type I
receptor (R4) in COS cells (Figure 2). FKBP12 was tagged
at its amino-terminus with a T7 tag, and coexpressed
Figure 1. Specific Interaction between TGFb Family Type I Recep- with either the wild-type R4, or the kinase-deficient R4
tors and FKBP12 mutant (R4K25R4K230R) in COS cells that were meta-
A yeast selective plate (Ura2 His2 Trp2 galactose plate with X-Gal) bolically labeled with [35S]methionine. Coimmunopreci-
containing yeast colonies expressing two fusion proteins, B42 fused pitation assays using the transfected COS cell lysates
to FKBP12 and LexA fused to cytoplasmic domains of different type
were carried out with monoclonal anti-T7 antibody. TheI and type II receptors, as indicated. aRII, activin type II receptor;
coprecipitated type I receptor was detected by autoradi-tRII, TGFb type II; and mRII, a putative MIS type II receptor (Teixeira
et al., 1996). ography (Figure 2). Both the wild-type and the kinase
FKBP12 Inhibits TGFb Family Type I Receptor Signaling
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suggesting that the type II receptor-mediated phosphor-
ylation of the type I receptor, not type I receptor auto-
phosphorylation, is necessary for the release of FKBP12.
To test whether phosphorylation of the two threonines
and three serines within the core sequence of the GS
domain TTSGSGSG of the TGFb type I receptor is re-
sponsible for releasing FKBP12, the threonines and ser-
ines were mutated to valines and alanines, respectively
(R4VVAAA). Like the wild-type R4, the R4VVAAA mutant
failed to coprecipitate with FKBP12 in the presence of
the wild-type type II receptor (Figure 3, lane 6), but co-
precipitated with FKBP12 in the presence of the kinase
deficient type II receptor (Figure 3, lane 5), indicating
that phosphorylation of these sites is not responsible
for releasing FKBP12.
Nonfunctional Derivatives of FK506 Can
Figure 3. FKBP12 Is Released from the Ligand-Bound TGFb Type Compete with the Type I Receptor
I Receptor for FKBP12 Binding in COS Cells
COS1 cells transiently transfected with the indicated constructs or Since the macrolide binding site of FKBP12 appears to
vector alone (EV) were affinity labeled two days after transfection be involved in binding to the type I receptors (Wang et
by incubation with [125I]-TGFb followed by disuccinimidyl suberate.
al., 1994), we directly tested whether the interactionCells were lysed in 500 ml of lysis buffer. Anti-T7 monoclonal anti-
between R4 and FKBP12 in COS cells can be blockedbody (5 ml) was added into cell lysates with equal counts of labeled
by an excess amount of macrolides. Both FK506 andreceptors for immunoprecipitation, in the absence (lanes 1–7) or
presence (lane 8) of 3 mg of T7 peptide. The immunoprecipitates rapamycin each alone exhibited growth inhibition ac-
were then separated on 10% SDS–polyacrylamide gel, which was tivities when added into the TGFb responsive mink
then subjected to autoradiography for 6 days. lung epithelial cell line (Mv1Lu); therefore, we turned to
two nonfunctional derivatives of FK506, L685,818 and
15-O-desmethyl-FK520. Both bind to FKBP12 at the
deficient mutant were coprecipitated with T7 tagged same site and with a similar affinity as FK506, but have
FKBP12 (Figure 2, lanes 3 and 4), indicating that the minimal cellular effects even at veryhigh doses,because
kinase activity of the type I receptor is not required for of their defect in calcineurin binding (Dumont et al., 1992;
FKBP12 binding, as was also observed in yeast. Liu et al., 1992; Becker et al., 1993). Both derivatives,
as illustrated by 15-O-desmethyl FK520 (10 nM), are able
to block R4/FKBP12 coimmunoprecipitation (Figure 4A,FKBP12 Is Released from the TGFb-Bound
lane 4), further confirming that the macrolide bindingActivated Type I Receptor
site of FKBP12 is involved in binding to the TGFb typeTo test how ligand-binding affects R4 interaction with
I receptor.FKBP12, R4 was cotransfected with TGFb type II recep-
tor (RII) and the T7 tagged FKBP12 into COS cells, and
activated by TGFb. The ligand-bound type I and type II Release of FKBP12 from the Type I Receptors
receptors were affinity labeled with [125I]-iodinated TGFb by FK506 Derivatives Enhances TGFb and
by chemical cross-linking (Massague´ and Like, 1985). MIS-Induced Functional Responses
Little, if any ligand-bound wild-type R4 was coprecipi- The ability of the nonfunctional FK506 derivatives to
tated with T7-tagged FKBP12 (Figure 3, lane 1), sug- block FKBP12 binding to the inactive TGFb type I recep-
gesting that FKBP12 is released from the ligand-bound tor allows us to address the functional role of FKBP12
type I/type II receptor complex. in type I receptor-mediated signaling events, in which
FKBP12 could play either a positive, or a negative role.
For example, if FKBP12 is responsible for transducingThe Type II Receptor Phosphorylates the Type I
Receptor within an Undefined Site the activation signal from the receptors to downstream
players through binding to the type I receptors, thento Release FKBP12
The type I receptor is known to be phosphorylated by blocking the binding with excess FK506 derivatives
should also block the signaling pathways; alternatively,the type II receptor in the presence of TGFb, and may
thus be activated as a kinase to autophosphorylate or if FKBP12 is an inhibitor of the type I receptors, excess
FK506 derivatives should help to activate the down-to phosphorylate unknown substrates (Wrana et al.,
1994a). To test whether these phosphorylation events stream events. In the mink lung epithelial cell line Mv1Lu,
TGFb causes transcriptional activation of the plasmino-are responsible for the observed release of FKBP12
from the ligand-bound R4, we replaced the wild-type gen activator inhibitor (PAI) promoter driving the lucifer-
ase reporter gene (3TP-Luc) (Wrana et al., 1992), as wellreceptors with the kinase deficient mutant receptors.
[125I]-TGFb-labeled receptor complexes were coprecipi- as cell cycle G1 arrest, monitored by a decrease in 3H-
thymidine incorporation. When excess 15-O-desmethyl-tated with FKBP12 only when the type II receptor kinase
was deficient (Figure 3, lanes 2 and 4), but not when the FK520 or L685,818 (500 nM) were added to Mv1Lu cells,
neither TGFb-induced response was blocked (data nottype I receptor kinase was deficient (Figure 3, lane 3),
Cell
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To determine whether FKBP12 is instead an inhibitor
of the type I receptor signaling, we first tested whether
abolishing FKBP12 binding to the type I receptor with
a high dose of FK506 derivatives can activate the down-
stream events in the absence of TGFb in Mv1Lu cells.
No significant gene activation responses were detected
when the derivatives were added alone (Figure 4B,
‘‘L685, 818’’), indicating that releasing FKBP12 from the
type I receptor alone is not sufficient to activate down-
stream pathways.This is not surprising, since the deriva-
tives only release FKBP12, but can not induce other
events known to be essential for the activation of the
type I receptor, such as the type II receptor mediated
GS domain phosphorylation (Wrana et al., 1994a), and
the release of the farnesyltransferase a subunit (FNTA)
(Wang et al., 1996). Therefore, the FKBP12-releasing
effect of the derivatives can only be detected in the
presence of TGFb. Since the release of FKBP12 is nor-
mally induced by the ligand/type I receptor binding (Fig-
ure 3), the specific effect of releasing FKBP12 by the
FK506 derivatives can be detected only if there are
threshold doses of TGFb, which are sufficient for induc-
ing other necessary activation events but not for releas-
ing FKBP12 completely. By adding the derivatives to-
gether with such doses of TGFb, the derivatives would
release the retained FKBP12, which may then lead to
an increase of the TGFb specific response, if FKBP12
binding is inhibitory to the signaling activity of the type
I receptor.
To find the threshold doses of TGFb, excess FK506
derivatives were added with different doses of TGFb
to Mv1Lu cells. No effect was detected when 1 mM
derivatives were added together with a maximal (250
pM) dose of TGFb. This is as expected, since a high
dose TGFb may completely release FKBP12. When 1
pM TGFb was added to Mv1Lu cells, it induced a 3- to
4-fold increase of the luciferase activity of the 3TP-Luc
reporter (Figure 4B, “TGFb”), which is normally induced
more than 100-fold by maximal dose (250 pM) of TGFb,
thus indicating a very weak activation of the signalingFigure 4. Nonfunctional Derivatives of FK506 Can Compete with the
TGFb Type I Receptor in Binding to FKBP12 and Thus Enhance pathways at this dose. When excess FK506 derivatives
TGFb Effects in Mv1Lu Cells (1 mM of either 15-O-desmethyl-FK520, or L685,818)
(A) Competition of 15-O-desmethyl-FK520 with R4 in binding to were added together with 1 pM TGFb, a 6- to 8-fold
FKBP12 in COS cells. COS1 cells transfected with the indicated increase of luciferase activity was detected (Figure 4B,
cDNAs in either pCMV8 (FKT7) or pCMV6 (R4) or pCMV8 vector “L685,818 1 TGFb’’). Therefore, although the deriva-alone (EV) were treated with or without 15-O-desmethyl-FK520, as
tives alone can not activate the 3TP-Luc (Figure 4B,indicated, and metabolically labeled with [35S]-methionine. Cells
“L685,818”), they can significantly potentiate low dosewere then lysed, and cell lysates were subjected to immunoprecipi-
TGFb-induced 3TP-Luc activation, by specifically re-tation using anti-T7 monoclonal antibody, either with (lane 2), or
without (lanes 1, 3, and 4) preincubation with excess T7 peptide. leasing FKBP12 from the type I receptor, suggesting
The immunoprecipitates were separated on 15% SDS–polyacryl- that FKBP12 binding is inhibitory to the type I receptor-
amide gel, which was then subjected to autoradiography. mediated signaling.
(B) Enhancement of the TGFb induced up-regulation of the 3TP-
Since FKBP12 binds to all known type I receptors, itsLuc reporter in Mv1Lu cells by L685,818. Mv1Lu cells transfected
inhibitory activity should also be detected in the signal-with p3TP-Lux reporter construct (control) were incubated with 200
ing events mediated by other TGFb family members.nM L685,818 alone (L685,818), or 1 pM TGFb alone (TGFb), or 200
nM L685,818 together with 1 pM TGFb (L685,8181TGFb). Luciferase Mu¨llerian inhibiting substance (MIS) is a member of the
activities were measured in the cell lysates as described in Experi- TGFb family responsible for regression of the Mu¨llerian
mental Procedures, with each point determined in triplicates. duct in fetal males through an active apoptotic process
(Jost, 1947; Price et al., 1977; Trelstad et al., 1982). The
shown). Thus FKBP12 binding to the TGFb type I recep- activity of MIS in the regression of the Mu¨llerian ducts
tor is not required for the activation of downstream sig- can be measured directly in an organ culture assay (Do-
naling events, suggesting that FKBP12 is not likely an nahoe et al., 1977). In this assay, urogenital ridges con-
taining both Wolffian and Mu¨llerian duct isolated fromactive signaling molecule.
FKBP12 Inhibits TGFb Family Type I Receptor Signaling
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Figure 5. MIS-Mediated Mu¨llerian Duct Regression Enhanced by FK506 Derivatives
(A) Hematoxylin- and eosin-stained paraffin sections of urogenital ridges in the organ culture. The dissected 14.5-day female rat urogenital
ridges containing the Wolffian duct (W) and the Mu¨llerian duct (M) were incubated in the presence of either 1 mg/ml MIS (top), or 1 mM
15-O-desmethyl-FK520 (bottom), or with 1 mg/ml MIS and 1 mM 15-O-desmethyl-FK520 (middle; n 5 3 for each panel). The depicted Mu¨llerian
duct regression in each panel is representative of the three tested ridges, which are similar.
(B) Regression activities of 2 mg/ml MIS in the presence of different doses of L685,818. More than 5 different individual ridges were assayed
at each dose and regression scored as described previously (Donahoe et al., 1977). For each dose, the percentage of ridges ranked within
specific regression grades are included.
(C) Regression activities of different doses of MIS, as indicated, in the presence or absence of 500 nM 15-O-desmethyl-FK520. More than
five ridges were assayed within each group.
14.5-day rat female fetuses, which have had no previous mg/ml MIS, 100% were grade 3; when 500 nM drug was
added together with 2 mg/ml MIS, 50% of the ridgesendogenous MIS exposure, are incubated with different
doses of exogenous MIS. Regression of the Mu¨llerian were grade 3 and 50% were grade 4, while ridges treated
with drugs alone were grade 0–1 (data not shown).duct is then monitored histologically and the degree
of the regression graded from 0 (no regression) to 5 Therefore, increasing concentrations of L685,818 pro-
gressively enhanced the Mu¨llerian duct regression. Dif-(complete regression) as described (Donahoe et al.,
1977). When 1 mg/ml MIS was added to the organ cul- ferent doses of MIS were also tested with 500 nM
15-O-desmethyl-FK520 (Figure 5C). In the presence ofture, grade 1 regression, characterized by condensation
of the mesenchymal cells surrounding a smaller and the drug, 0.25 mg/ml MIS can cause grade 2 regression
in more than 70% of the ridges, while 1 mg/ml MIS aloneirregularly shaped Mu¨llerian duct, was observed (Figure
5A, top). When 1 mM 15-O-desmethyl-FK520 alone was can cause grade 2 regression in only 25% of the ridges.
Grade 4 regression was achieved when 2 mg/ml MIS wasadded to the organ culture, no regression was detected
(Figure 5A, bottom). However, when 1 mM 15-O-des- added together with the drug, while the same degree
of regression activity normally requires more than 5 mg/methyl-FK520 was added together with 1 mg/ml of MIS,
the duct was replaced by a cord of pycnotic epithelial ml MIS.
These data indicate that FKBP12 also inhibits the MIS-cells and connective tissue (grade 4) (Figure 5A, middle).
We further tested the effect of four different doses of induced signaling pathway, and that Mu¨llerian duct re-
gression induced by MIS can be significantly enhancedL685,818 on the regression activity of 2 mg/ml MIS. At
least five organ cultures were carried out for each tested by addition of the nonfunctional FK506 derivatives.
Since FKBP12 interacts with all members of the TGFbdose of L685,818 alone (data not shown), or L685,818
with 2 mg/ml MIS, the results of which were represented family type I receptors through two highly conserved
type I receptor-specific domains (T. Wang et al., unpub-by the percentage of the Mu¨llerian ducts ranked within
each regression grade (Figure 5B). When treated with 2 lished data), we can anticipate that the nonfunctional
FK506 derivatives can produce similar effects on othermg/ml MIS alone, 50% of ridges were grade 1, and 50%
were grade 2;when 50 nM L685, 818 was added together members of the TGFb family. These data also suggest
that the nonfunctional derivatives of FK506 may havewith 2 mg/ml MIS, 75% were grade 2 and 25% were
grade 3; when 250 nM drug was added together with 2 exciting therapeutic applications: one might use low
Cell
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dose TGFb family ligands for targeted specificity, with
addition of FK506 nonfunctional derivatives to potenti-
ate the biological activities, thus reducing potential clini-
cal side effects caused by high dose TGFb family li-
gands.
Myristylated Wild-Type FKBP12 But Not a
Calcineurin-Binding-Deficient FKBP12
Mutant Specifically Blocks
TGFb Responses
If, as our data suggests, FKBP12 functions as an inhibi-
tor of the type I receptor, its release from the ligand-
bound type I receptor should be essential for the activa-
tion of the ligand-induced downstream events, and
blocking its release should also inhibit the type I recep-
tor-mediated signaling. There are two possible ways to
block the release of FKBP12: first, by abolishing the
phosphorylation site on the type I receptor responsible
for releasing FKBP12; second, by fusing FKBP12 with
the cytoplasmic domain of the type I receptor. Since
theprecise phosphorylation site responsible for FKBP12
release has yet to be identified, and direct fusion of
FKBP12 to the type I receptor interfered with the func-
tional conformation of the type I receptor (data not
shown), we tested whether the inhibitory activity of
FKBP12 could be detected by localizing FKBP12 to the
cell membrane to increase its local concentration
around the membrane-bound type I receptor. A 13
aminoacid src myristylation sitewas placed at the amino
terminus of FKBP12 in a mammalian expression vector
pBJ5 (Clipstone and Crabtree, 1992). Overexpression of
this construct (mFE) in Mv1Lu cells greatly reduced the
TGFb induced 3TP-Luc luciferase activities (from 150-
to 25-fold) (Figures 6A and 6B, ‘‘control’’ and ‘‘mFE’’).
To rule out nonspecific toxicity resulting from overex-
pressing FKBP12 at the membrane, we used mFE in
another TGFb response assay, the TGFb-dependent
suppression of a cyclin A promoter driven luciferase
Figure 6. Myristylated Wild-Type FKBP12 But Not a Calcineurin-reporter (Figures 6C and 6D). Unlike the 3TP-Luc re-
Binding-Deficient FKBP12 Mutant Specifically Blocks TGFb Re-
porter, which is transcriptionally up-regulated by TGFb sponses
and monitors the pathway that leads to increased pro- (A) Mv1Lu cells were transfected with 3TP-Luc alone (control), or
duction of the extracellular matrix, the cyclin A-Luc re- with 3TP-Luc and the myristylated FKBP12 in PBJ5 (mFE), or with
porter is transcriptionally downregulated by TGFb and 3TP-Luc and the myristylated mutant FKBP12 in PBJ5 (mFpkE).
Equal amount of myristylated wild-type FKBP12 and the mutantmonitors the pathway that leads to cell cycle G1 arrest
FKBP12 are expressed, as determined by Western blot using anti-(Feng et al., 1995). A specific inhibition of the TGFb
FKBP12 antiserum (data not shown). The luciferase activities wereresponse by overexpression of myristylated FKBP12
measured as described in Experimental Procedures. The arbitrary
should block TGFb-induced down-regulation of the lu- units, with error bars, are presented. The experiments were per-
ciferase activity from the cyclin A-Luc reporter, which formed twice, with each point determined in triplicates.
should be reflected in an increase in the luciferase activ- (B) The arbitrary units in (A) from the TGFb-treated cells were divided
by those from the untreated cells to show fold of increase of theity in the mFE-transfected, TGFb-treated Mv1Lu cells
luciferase activity upon TGFb treatment.when compared with the untransfected, TGFb-treated
(C) Same as (A), except the cells were transfected with cyclin A-LucMv1Lu cells. A nonspecific toxicity effect of myristyl-
reporter rather than 3TP-Luc.
ated FKBP12, however, should cause a further decrease (D) The arbitrary units in (C) from untreated cells were divided by
of the luciferase activity in the TGFb-treated, mFE- those from the TGFb-treated cells to show fold of decrease of the
transfected cells. Overexpression of mFE almost com- luciferase activity upon TGFb treatment.
(E) A cartoon to depict a potential mechanistic difference betweenpletely blocked the TGFb-induced repression of the
the endogenous free cytoplasmic FKBP12 (control), the membrane-cyclin A-Luc reporter, indicating that the myristylated
bound myristoylated FKBP12 (mFE) and the membrane-bound myri-FKBP12 can specifically inhibit two separate pathways
stylated calcineurin-binding-deficient FKBP12 (mFpkE), during li-
activated by TGFb in Mv1Lu cells (Figures 6C and 6D, gand-induced activation of the TGFb type I receptor. See text for
‘‘control’’ and ‘‘mFE’’). Since FKBP12 is normally re- details.
leased from the type I receptor upon ligand binding
(Figure 3), the myristylated FKBP12, although not free
FKBP12 Inhibits TGFb Family Type I Receptor Signaling
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to travel into the cytoplasm, should also be dissociated can be abolished by FK506 derivatives that have the
same FKBP12 binding properties as FK506 but lack thefrom the ligand-bound type I receptor. Therefore, the
calcineurin binding domain, and thus lack functionalinhibitory activity of the myristylated FKBP12 is not likely
immunosuppressive activity (Dumont et al., 1992; Liu etmediated by its direct interaction with the type I re-
al., 1992; Becker et al., 1993). Based upon this observa-ceptor.
tion, we used the nonfunctional FK506 derivatives toAn alternative mechanism for the inhibitory activity of
specifically disrupt the FKBP12/type I receptor interac-the myristylated FKBP12 is suggested by overexpres-
tion in both a TGFb-responsive cell line, Mv1Lu, and ansion of a mutant myristylated FKBP12 (G89P, I90K) in
MIS responsive organ, the fetal Mu¨llerian duct. By find-Mv1Lu cells. These mutations are known to be located
ing doses of either TGFb or MIS that were sufficientlywithin the 80s loop of FKBP12 and to abolish calcineurin
low to retain FKBP12, yet adequate to induce otherbinding without affecting either FK506 binding or
activation events, a specific enhancement of TGFb re-FKBP12 prolyl-isomerase activity (Yang et al., 1993). The
sponses was uncovered in Mv1Lu cells, and an augmen-mutant (mF(pk)E) failed to inhibit either of the TGFb-
tation of the degree of Mu¨llerian duct regression wasdependent pathways (Figure 6, ‘‘mF(pk)E’’). This data
observed in a large number of organ culture assays.further indicates that FKBP12 may inhibit the type I re-
These data revealed, for the first time, that FKBP12ceptor by docking a cytoplasmic inhibitor, such as cal-
binding to the type I receptor is physiological and iscineurin, as depicted by the cartoon (Figure 6E). Before
inhibitory to the signaling activity of the receptors. Sinceligand binding, FKBP12 docks the inhibitor to the type
detecting the FKBP12-releasing effect by the FK506 de-I receptor, thus preventing receptor signaling. Upon li-
rivatives is dependent upon the dissociation of the li-gand binding, the type II receptor phosphorylates the
gand-induced FKBP12 release from other activationtype I receptor to release FKBP12 and with it, the associ-
events by using threshold dose ligand, the relativelyated inhibitor (see Figure 6E, “Control”). The overex-
weaker enhancement effect of the derivatives on thepressedmyristylated FKBP12 competes with the endog-
TGFb-induced gene response, in comparison to the ef-enous FKBP12 to bind to the ligand-free type I receptor,
fect on the MIS-induced Mu¨llerian duct regression, mayand cannot be released into the cytoplasm upon ligand-
reflect a less successful dissociation of the ligand-induced phosphorylation of the type I receptor, due to
induced FKBP12 release from the rest of the activationits anchorage to the membane, thus allowing the cyto-
events.
plasmic protein to inhibit the type I receptor in the pres-
The inhibitory activity of FKBP12 was further tested
ence of ligand (see Figure 6E, “mFE”). The overex-
by overexpression of a myristylated FKBP12 in Mv1Lu
pressed mutant FKBP12, although localized to the
cells. Strong and specific inhibition of two separate
membrane, fails to dock the inhibitor to the type I recep- pathways mediated by TGFb were detected. The inhibi-
tor, either before, or after ligand binding to the type I
tory activity of the myristylated FKBP12 was abolished
receptor. Therefore, normal signaling activity of the type by two point mutations known to disrupt FKBP12 bind-
I receptor is detected (see Figure 6E, “mF(pk)E”). ing to calcineurin, but not FKBP12 prolyl-isomerase ac-
tivity (Yang et al., 1993). Since ligand-induced type I
receptor phosphorylation releases FKBP12, we there-Concluding Remarks
fore can conclude that the inhibitory activity of FKBP12
is not mediated by its prolyl-isomerase activity, nor by
Much is known about the growth stimulatory pathways
its direct binding to the type I receptor, but more likely
mediated by tyrosine kinase receptors, while little is by its ability to dock a cytoplasmic inhibitor of the type
known about the growth inhibitory pathways activated I receptor.
by the serine/threonine kinase receptors of the TGFb One candidate for such an inhibitor is calcineurin.
family. The evolutionarily conserved, abundant cyto- FKBP12 is known to bind to calcineurin with high affinity
plasmic protein FKBP12 is known to bind exogenous in the presence of the macrolide FK506. In the absence
macrolide molecules to mediate immunosuppression; of FK506, FKBP12 has a weak butspecific and functional
however, its normal physiological roles remain obscure. interaction with calcineurin in yeast (Cardenas et al.,
By using the yeast two-hybrid system, we identified 1994). Recently, FKBP12 was shown to recruit cal-
FKBP12 as a common interactor of several cytoplasmic cineurin to the IP3 receptor where calcineurin dephos-
domains of the TGFb family type I serine/threonine ki- phorylates specific sites on the IP3 receptor to regulate
nase receptors. Recent domain mapping studies re- Ca21 influx (Cameron et al., 1995). Interestingly, FK506
vealed that two highly conserved type I receptor specific can compete with both the IP3 receptor and the TGFb
motifs are essential for the FKBP12/type I receptor bind- type I receptor to bind FKBP12, suggesting that similar
ing (T. W. et al., unpublished data), which explains the motifs of the receptors are involved in binding to the
molecular basis for the observed binding specificity for same FK506 binding site of FKBP12. The known binding
all known type I receptors. Using the TGFb type I recep- sites on FKBP12 for calcineurin and for FK506 are imme-
tor as a model, we demonstrated coimmunoprecipita- diately adjacent to each other (Yang et al., 1993; Kis-
tion of FKBP12 with the ligand-free type I receptor when singer et al., 1995). Therefore, binding of the TGFb family
both proteins were coexpressed in COS cells. In the type I receptors and the huge IP3 receptor to the FK506
same system, we further demonstrated that FKBP12 is binding site of FKBP12 suggests that calcineurin, if also
released from the ligand-bound type I receptor, and that directly bound to FKBP12 in the receptor/FKBP12/cal-
the release is dependent upon type II receptor mediated cineurin complex, must be binding to sites removed
phosphorylation of the type I receptor within an unde- from the FK506 binding site of FKBP12. Since cal-
cineurin is a serine/threonine phosphatase, while typefinedsite. Interestingly, the receptor/FKBP12 interaction
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of an additional site to release FKBP12 and its docked
inhibitor. Alternatively, complete activation of the type
I receptor can be accomplished by using low dose TGFb
to complete (1), and then excess nonfunctional FK506
derivatives to release FKBP12 and its associated inhibi-
tor. Additional mechanisms involved in the direct inacti-
vation of the inhibitor docked by FKBP12, such as phos-
phorylation of the inhibitor, may also be required during
the normal activation of the type I receptor by high dose
ligand. Once activated, the type I receptor may then
phosphorylate a cytoplasmic substrate, which could be
bound to the phosphorylated GS domain, or to other
phosphorylated domains. The phosphorylated cyto-
plasmic substrate(s), together with the released and
phosphorylated a subunit of the farnesyltransferase
(Wang et al., 1996), are then responsible for transducing
the activation signals downstream. Future studies to
map the phosphorylation site(s) responsible for the re-
lease of FKBP12, to identify the substrates of the type
I receptor kinase, and to dissect the signaling role of
the farnesyltransferase a subunit will provide important
information for understanding the activation events at
or downstream of the TGFb family type I receptors.
Experimental Procedures
Strains and Cell Lines
The yeast strain EGY48 MATa trp1 ura3 his3 LEU2::pLexAop6-LEU2,
the E. coli K-12 strain KC8 pyrF::Tn5, hsdR, leuB600, trpC9830,
lacD74, strA, galK, hisB436 are gifts from Dr. Roger Brent (Massa-
chusetts General Hospital, Boston). The mink lung epithelial cell line
Figure 7. A Model for the Events Involved in the Activation of the Mv1Lu is a gift from the Massague´ laboratory.
TGFb Type I Receptor.
Plasmids and Plasmid ConstructionSee text for details.
The multiple LexA and B42 fusion constructs were made by PCR
amplification of the designed cDNA sequences with two restriction
sites attached at 59 (EcoRI) and 39 (XhoI) ends for subcloning into
I receptors are serine/threonine kinases, and phosphor- the respective sites within the multiplecloning sites of either pEG202
ylation of the type I receptor as well as its downstream and pJG4-5 (Gyuris et al., 1993, Zervos et al., 1993). Mammalian
expression constructs of TGFb type I (He et al., 1993) and type IIsubstrates is essential for signaling via the type I recep-
receptors and their kinase deficient mutants were described pre-tors, one plausible mechanism for calcineurin to inhibit
viously (Bassing et al., 1994). R4VVAAA was a gift from Dr. Jefferythe type I receptor signaling activity is to dephosphory-
Wrana. The T7 tagged FKBP12 was made by first subcloninglate the type I receptor, or its bound substrates. It will be
FKBP12 cDNA into EcoRI/XhoI sites of plasmid PET 28a (Novogen)
necessary to detect the ternary complex of calcineurin/ and then subcloned into the pCMV8 vector (from Dr. David Russel).
FKBP12/type I receptor and these dephosphorylation Plasmids mFE and mFpkE in pBJ5 are generous gifts from Dr. Stuart
Schreiber at Harvard. The 3TP-Luc reporter is from Dr. Jefferyevents in vivo to provide the final proof for such a mech-
Wrana. The cyclin A-Luc reporter is from Dr. Rik Derynck.anism.
The model in Figure 7 summarizes our observations
Yeast Two-Hybrid Screenon the inhibitory role of FKBP12 and our hypothesis
We used a modified version of the yeast two-hybrid system devel-
regarding its potential link to other known events in- oped by Roger Brent and his colleagues, as previously described
volved in the activation of the TGFb type I receptor. in detail (Gyuris et al., 1993; Zervos et al., 1993).
Before TGFb binding, FKBP12 binds to the type I recep-
tor, and recruits a cytoplasmic inhibitor, such as cal- COS Cell Transfection, Metabolic Labeling, Receptor
Cross-Linking, Immunoprecipitation,cineurin, to keep the type I receptor inactive, possibly
and Western Blotby keeping the type I receptor and its interactor(s), such
For testing FKBP12 binding to ligand-free TGFb type I receptor byas the a subunit of the farnesyltransferase (Wang et al.,
coimmunoprecipitation, COS1 cells grown in P-100 dishes were
1996), hypophosphorylated. The complete activation of transfected with 4 mg of T7 tagged FKBP12 in pCMV8 and 6 mg of
the type I receptor can be accomplished in one of two R4 (or mutant R4) in pCMV6, using the DEAE-dextran method. In
the case of using metabolic labeling to detect coprecipitation ofways. Naturally, high dose TGFb induces the formation
FKBP12 and R4, 40–44 hr after transfection COS1 cells were incu-of a tetrameric active signaling complex between the
bated for 4 hr with 50 mCi/ml [35S]-methionine in methionine-freetype I and the type II receptors (Weis-Garcia and Mas-
media and lysed in lysis buffer (20 mM Tris-HCl [pH 7.4], 150 mMsague´, 1996), in which possible sequential activation
NaCl, 0.5% Triton X-100, 1 mM EDTA) in the presence of a mixture
events occur, involving: (1) GS domain phosphorylation of protease inhibitors. Anti-T7 monoclonal antibody (5 ml) was added
and release of the a subunit of the farnesyltransferase, into 200 ml of cell lysates, incubated at 48C for 2 hr, absorbed with
protein A sepharose beads, and washed three times with washand probable additional events, and (2) phosphorylation
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buffer (20 mM Tris-HCl [pH 7.4], 150 mM NaCl, 0.1% Triton X-100, Becker, J.W., Rotonda, J., McKeever, B.M., Chan, H.K., Marcy, A.I.,
Wiederrecht, G., Hermes, J.D., and Springer, J.P. (1993). FK-506-1 mM EDTA). Proteins were eluted from the sepharose beads using
23 SDS–polyacrylamide gel electrophoresis (SDS–PAGE) denatur- binding protein: three-dimensional structure of the complex with
the antagonist L-685,818. J. Biol. Chem. 268, 11335–11339.ing sample buffer, separated on 15% SDS–polyacrylamide gel.
For testing the effect of nonfunctional FK506 derivatives (L685,818 Border, W.A., and Ruoslahti,E.J. (1992). Transforming growth factor-
from Merck Laboratories and 15-O-desmethyl-FK520 from Sandoz) beta in disease: the dark side of tissue repair. J. Clin. Invest. 90,
on FKBP12 binding to R4, 2 hr after transfection COS1 cells were 1–7.
treated with the derivatives for 40–44 hr and then labeled for 4 hr
Brown, E.J., Albers, M.W., Shin, T.B., Ichikawa, K., Keith, D.T., Lane,
with 50 mCi/ml [35S]-methionine in methionine-free. Cells were then
W.S., and Schreiber, S.L. (1994). A mammalian protein targeted by
lysed and immunoprecipitation was carried out as described above.
G1-arresting rapamycin-receptor complex. Nature 369, 756–758.
For testing FKBP12 binding to the ligand-bound type I receptor,
Brown, E.J., Beal, P.A., Keith, C.T., Chen, J., Bumshin, T., Schreiber,COS cells were transfected with 4 mg of T7-FKBP12 pCMV8, 6 mg
S.L. (1995). Control of p70S6 kinase activity of FKAP in vivo. Natureof R4 (or R4K2)pCMV6 and 5 mg of RII (or RIIK2)pcDNA1. Forty-eight
377, 441–446.hours after transfection, cells were incubated for 3 hr at 48C with
Brummel, T.J., Twombly, V., Marque´s, G., Wrana, J.L., Newfeld,[125I]-labeled TGFb at 250 pM. Cross-linking of receptor with the
M.B., Attisano, L., Massague´, J., O’Connor, M.B., and Gelbart, W.M.ligand was carried out as described previously (Massague´ and Like,
(1994) Characterization and relationship of Dpp receptors encoded1985). Cells were lysed in lysis buffer as above followed by immuno-
by the saxophone and thick veins genes in Drosophila. Cell 78,precipitation, SDS–PAGE, and autoradiography.
251–261.
Urogenital Ridge Organ Culture Assay Cameron, A.W., Steiner, J.P., Roskams, A.J., Ali, S.M., Ronnett, G.V.,
The organ culture assay was carried out as described previously and Snyder, S.H. (1995). Calcineurin associated with the inositol
(Donahoe et al., 1977). To test the effect of the nonfunctional deriva- 1,4,5-trisphosphate receptor-FKBP12 complex modulates Ca21 flux.
tives of FK506 (L685,818 or 15-O-desmethyl FK520) on Mu¨llerian Cell 83, 463–472.
duct regression, the specimens were treated with the indicated Cardenas, M.E., Hemenway, C., Muir, R.S., Ye, R., Fiorentino, D.,
doses of MIS in the presence or absence of the nonfunctional deriva- and Heitman, J. (1994). Immunophilins interact with calcineurin in
tives of FK506. For each dose of MIS or MIS plus the FK506 deriva- the absence of exogenous immunosuppressive ligands. EMBO J.
tives, more than five individual urogenital ridges were assayed and 13, 5944–5957.
graded, and the ordinal results represented by the percentage of
Clipstone, N.A., and Crabtree, G.R. (1992). Identification of cal-the ridges that ranked within a specific regression grade.
cineurin as a key signalling enzyme in T-lymphocyte activation. Na-
ture 357, 695–697.Transcriptional Response Assay
Donahoe, P.K., Ito, Y., and Hendren, W.H., III. (1977). A graded organThe TGFb responsive mink lung epithelial cell lines MvlLu were
culture assay for the detection of Mu¨llerian Inhibiting Substance. J.used in transcriptional response assays employing a DEAE-dextran
Surg. Res. 23, 141–148.transfection method (Bassing et al., 1994; Wrana, 1994a). In brief,
cells grown to 50% confluency in 6-well plates were transiently Dumont, F.J., Staruch, M.J., Koprak, S.L., Siekierka, J.J., Lin, C.S.,
transfected with 1 mg of either the transcriptional response reporter Harrison, R., Sewell, T., Kindt, V.M., Beattie, T.R., Wyvratt, M., and
construct p3TP-lux, or cyclin A-Luc, alone, or together with 1 mg of Sigal, N.H. (1992). The immunosuppressive and toxic effects of FK-
mFE or mFpkE in PBJ5. Sixteen to twenty hours after transfection, 506 are mechanistically related: pharmacology of a novel antagonist
cells were treated with TGFb in 0.2% serum medium for 24–28 hr. of FK-506 and rapamycin. J. Exp. Med. 176, 751–760.
For testing the effect of FK506 derivatives, cells were treated with Ebner, R., Chen, R.-H., Shum, L., Lawler, S., Zioncheck, T.F., Lee,
the drug beginning 2 hr prior to the addition of TGFb. Cell lysates A., Lopez, A.R, and Derynk, R. (1993). Cloning of a type I TGF-b
were made and luciferase activity was measured in a luminometer. receptor and its effect on TGF-b binding to the type II receptor.
Each assay was carried out in triplicates. Science 260, 1344–1348.
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